Tempest Therapeutics, Inc. (TPST): Submission of Matters to a Vote of Security Holders
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On November 9, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”). The final results for each of the proposals submitted to
How this was made
The 30-second read
Why it matters
The disclosures are routine governance updates with limited immediate price impact, but they confirm the company’s ability to raise capital under Nasdaq rules.
Market read
The filing provides the first public record of the vote outcomes; while material for governance, it offers little actionable trading insight.
What to watch
Potential future capital raises tied to the approved Lincoln Park and PIPE proposals may affect share count.
Background
Tempest Therapeutics filed an 8‑K to disclose the final vote counts from its 2026 annual meeting, covering director elections, auditor ratification, and approval of stock‑issuance plans.
Ticker impact
SEC 8‑K reports the results of Tempest Therapeutics' 2026 annual shareholder meeting votes on directors, auditor, and stock issuance proposals.
minimal impact as the results are expected and do not change fundamentals
The filing discloses only vote tallies for standard proposals; no new financing, acquisition, or material change is announced.
Market effects
None; the filing pertains to a single biotech firm and does not affect the broader sector.
None; the company is US‑listed and the news is company‑specific.
None
Counterpoint
If the vote reveals dissent on the stock‑issuance proposal, it could signal future dilution concerns.
Key entities
- companyTempest Therapeutics, Inc.
Biotech firm filing the 8‑K.
- entityLincoln Park Capital Fund, LLC
Partner in the approved stock‑issuance proposal.